Scholar Rock Holding Co. (NASDAQ:SRRK) Position Boosted by Sei Investments Co.

Sei Investments Co. lifted its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 4.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,314 shares of the company’s stock after purchasing an additional 3,940 shares during the period. Sei Investments Co. owned about 0.09% of Scholar Rock worth $3,774,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 766 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares during the last quarter. Amalgamated Bank raised its position in shares of Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after purchasing an additional 620 shares during the period. Finally, KBC Group NV purchased a new stake in shares of Scholar Rock during the fourth quarter valued at $131,000. 91.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Tracey Sacco sold 6,500 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares in the company, valued at approximately $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Katie Peng sold 1,006 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. This represents a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 299,772 shares of company stock worth $11,245,798. Corporate insiders own 19.20% of the company’s stock.

Scholar Rock Trading Up 8.3 %

NASDAQ:SRRK opened at $32.54 on Thursday. The stock’s 50-day moving average is $36.94 and its two-hundred day moving average is $33.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market cap of $3.08 billion, a PE ratio of -13.85 and a beta of 0.59. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98.

Analyst Ratings Changes

Separately, Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.